Last reviewed · How we verify
NCT04216550
Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas
trial testing Apatinib in Recurrent Glioma in 600 participants. Status unknown.
1 January 2025
Quick facts
| Lead sponsor | The First Affiliated Hospital of Zhengzhou University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 1 January 2018 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Apatinib (Apatinib) — full drug profile →
Conditions studied
- Recurrent Glioma — all drugs for Recurrent Glioma →
Sponsor
The First Affiliated Hospital of Zhengzhou University
Who can join
Adults 18 to 90, any sex, with Recurrent Glioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Artificial Intelligence in Neurosurgery: A State-of-the-Art Review from Past to Future.
Tangsrivimol JA, Schonfeld E, Zhang M, Veeravagu A, et al · · 2023 · cited 43× · PMID 37510174 · DOI 10.3390/diagnostics13142429 -
FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.
Gött H, Uhl E. · · 2022 · cited 16× · PMID 35955806 · DOI 10.3390/ijms23158675 -
Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials.
Liu X, Chen Z, Wang X, Yan P, et al · · 2025 · cited 1× · PMID 41050932 · DOI 10.1016/j.isci.2025.113521
Verify or expand the search:
- PubMed search for NCT04216550
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Apatinib
Trials testing the same drug.
- NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
- NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
- NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
- NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
- NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting
Other recruiting trials for Recurrent Glioma
Currently open trials in the same condition.
- NCT07074756 — A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma · NA · recruiting
- NCT05859334 — Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment · Phase 2 · recruiting
- NCT05660369 — CARv3-TEAM-E T Cells in Glioblastoma · Phase 1 · recruiting
- NCT05045027 — Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma · EARLY_PHASE1 · active not recruiting
- NCT03212274 — Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations · Phase 2 · active not recruiting
Other The First Affiliated Hospital of Zhengzhou University trials
Trials by the same sponsor.
- NCT07501962 — Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate · NA · not yet recruiting
- NCT07501975 — Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality · NA · not yet recruiting
- NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
- NCT05114941 — Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome · NA · not yet recruiting
- NCT07314619 — Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combi · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04216550 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Zhengzhou University
- Last refreshed: 8 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04216550.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing